BDRX News and Press, Biodexa Pharmaceuticals PLC-ADR From 05/22/25

May 22, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment ...

2025-05-22 14:00:36 ET Sunrun Sinks 39% on House Passage of Energy Tax Rollback Sunrun Inc. ( RUN ) plunged 39.35% to lead losses in the PRISM Emerging New Energy Index after the House passed a tax-and-spending package that deals a major blow to clean energy incentives. The bi...

May 22, 2025 Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company...

urban-gro Inc. (UGRO) is expected to report for quarter end 2025-03-31 Karman Holdings Inc. (KRMN) is expected to report $0.02 for Q1 2025 PyroGenesis Inc Com (PYRGF) is expected to report for quarter end 2025-03-31 GeoVax Labs Inc. (GOVX) is expected to report $-0.59 for Q1 2025 ...

May 12, 2025 Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP New designation follows the U.S. Food and Drug Administration (FDA) Orphan Drug Designation for eRapa in FAP granted in 2019 Company nears start of Registrational Phase 3 study targeted at...

April 11, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2024 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisitio...

2025-03-19 08:16:27 ET DENVER, Colo., Mar 19, 2025 ( 247marketnews.com )- Biodexa Pharmaceuticals (NASDAQ: BDRX ) is charging toward the launch of a Phase 3 trial for eRapa, its proprietary rapamycin tablet aimed at treating familial adenomatous polyposis (FAP). With FDA Fast Track ...

2025-03-19 07:35:03 ET DENVER, Colo., Mar 19, 2025 ( 247marketnews.com )- Kraig Biocraft Laboratories (OTCQB:KBLB), a leader in innovative biomaterials, announced the groundbreaking achievement of its largest-ever single batch production of BAM-1 recombinant spider silk. This ma...

CARDIFF, UNITED KINGDOM / ACCESS Newswire / March 19, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is making progress in readying the launch o...

2025-03-10 09:28:22 ET DENVER, Colo., Mar 10, 2025 ( 247marketnews.com )- Biodexa Pharmaceuticals (NASDAQ: BDRX ) announced a successful Type C meeting with the U.S. Food and Drug Administration (FDA), paving the way for its registrational Phase 3 study of eRapa in familial adenomat...